Providing better service for vesicles analysis

Exosomics implements NanoFCM’s NanoAnalyzer at its Siena site

Register for free to listen to this article
Listen with Speechify
SIENA, Italy & NOTTINGHAM, U.K.—Exosomics SpA, which bills itself as the leading extracellular vesicles biotech company, recently announced that it has implemented NanoFCM’s NanoAnalyzer instrument to offer “sophisticated” contract research and measurement services worldwide. In this strategic partnership, Exosomics becomes NanoFCM’s approved service supplier of nano-flow cytometry measurements. These can be performed as a standalone service or coupled to solutions provided by Exosomics.
“Thanks to their NanoAnalyzer, Exosomics will be able to supply the widest range of nano-flow cytometry measurements, which are in high demand across Europe and the rest of the world,” said Dr. Dimitri Aubert, managing director of NanoFCM. “We are delighted to recommend Exosomics to our close collaborators wishing to access the NanoAnalyzer platform on a punctual basis, or as part of a wider range of services that would accelerate internal research and development capabilities.”
Added Dr. Antonio Chiesi, CEO of Exosomics: “We believe that by implementing the nano-flow cytometry platform, we are once more leading the extracellular vesicles research field and we can offer the widest range of services to biotech/pharma and academic groups. This instrument will also allow us to further develop our own liquid biopsy pipeline, which requires the highest level of accuracy and reproducibility.”
The NanoAnalyzer is designed for research use only. It is not for use in diagnostic procedures.
Established in 2012 and hosted in one of the largest and more active bio-parks in Italy, Tuscany Life Sciences, Exosomics is active in the area of liquid biopsy in cancer. After several years of research and development work and intellectual property development, it is now at commercial stage, launching its proprietary and innovative solutions into the molecular diagnostics market. Exosomics says that its distinguishing factor is the capability to isolate tumor-derived exosomes through proprietary affinity methods—thus enriching for tumor-derived proteins, DNA and RNA—and therefore significantly improving molecular diagnostics in cancer and allowing early pan-cancer screening.
Given that tumor-derived exosomes contain biomarkers identical to those expressed on a cancer cell surface, and are poorly expressed in healthy individuals, Exosomics considers exosome-based liquid biopsy as the next generation of cancer diagnostics, which will not only complement but surpass traditional biopsy.
NanoFCM is a privately held company based in Xiamen, China, which focuses on the development of high-performance analytical instruments. It has developed a next-generation nanoparticle analysis platform, the NanoAnalyzer, based on nano-flow cytometry. The company states that it is unique in its ability to deliver comprehensive measurement (size, concentration and phenotyping) down to 10 nm to 40 nm, depending on the nature of the substrate.

Published In:

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue